A 12-year-old Rottweiler dog was presented with a history of prostration, weight loss and hyporexia for six months. Based on complete blood tests (hematological and biochemical analyses), bone marrow examination and imaging analysis, a diagnosis of chronic myeloid leukemia was made. Treatment with hydroxyurea at a dosage of 18 mg/kg twice daily was not effective in controlling the high count of white blood cells. Furthermore, after 35 days of hydroxyurea treatment, the animal developed onycholysis, with sloughing of the claws of the left pelvic and left thoracic limbs and exposure of the distal phalanx. Interruption of the medication was implemented, with clinical healing of the ungual lesions observed three months after initiation of the drug. White blood cells returned to normal after using cyclophosphamide. Currently, the animal is in complete remission, having a disease-free interval of 575 days without chemotherapy. To the authors' knowledge, this is the first report of hydroxyurea-induced onycholysis within a short-term period in a dog diagnosed with chronic myeloid leukemia.
Background
Hydroxyurea is a ribonucleotide reductase inhibitor that leads to decreased DNA synthesis in the S phase of the cell cycle, resulting in cell death. 1 In veterinary medicine, its clinical use covers a variety of tumor-related disorders including bone marrow disorders such as chronic granulocytic leukemia, polycythemia vera, essential thrombocythemia and hypereosinophilic syndrome; 2À6 mast cell tumors 7 and meningiomas. 8 In human patients, hydroxyurea can be used to treat sickle-cell disease, melanoma, chronic myelogenous leukemia, ovarian tumor, squamous cell carcinoma of the head and neck, renal carcinoma, bladder urothelial carcinoma, prostate carcinoma and carcinoma of the uterine cervix. 9 Although hydroxyurea is usually tolerable, this drug has a low margin of safety, with myelosuppression being the most common dose-limiting side effect in human and animal patients. 10, 11 Anemia is the most commonly observed side effect in dogs, with delay of growth, arrest of spermatogenesis and hepatic/splenic hemosiderosis being additional common side effects. 11 Severe pneumonitis is also observed in humans.
14 Mucocutaneous manifestations such as xerosis, diffuse cutaneous hyperpigmentation, pseudo-dermatomyositis lesions, stomatitis and nail changes (nail peeling, melanonychia, onycholysis/onychomadesis), although rare, have been observed after long use of therapy in human patients and dogs. 1, 12, 13 The aim of this report is to describe a case of a dog with chronic myeloid leukemia that developed onycholysis secondary to treatment with hydroxyurea.
Case presentation
A 12-year-old intact female Rottweiler dog weighing 28 kg was referred to the Veterinary Teaching Hospital with history of prostration, weight loss and hyporexia for six months. On physical exam, physiological parameters were within the normal ranges, with no fever. Analysis of hematological parameters revealed normocytic normochromic anemia, leukocytosis with left shift (80,800/mL; neutrophils: 75,952/mL, band neutrophils: 1,616/mL), thrombocytosis (541 £ 10 3 /mL) and hypoalbuminemia (1.4 g/dL), without biochemical changes in alanine aminotransferase, alkaline phosphatase, urea and creatinine as well as no alterations in urinalysis. Three-view thoracic radiographic study and abdominal ultrasound did not reveal any abnormalities. Doppler echocardiogram and electrocardiogram values were also within normal reference values. A rapid immunochromatographic test was performed for distemper (Immunoassay kit for rapid and qualitative detection of CDV antigen, Alere Ò S.A., São Paulo, SP, Brazil) and ehrlichiosis (Immunocomb Ò canine ehrlichia antibody IgG test, VP diagnostic, São Paulo, SP, Brazil), which yielded negative results. Based on the hematological parameters and above-described results, an occult infection was suspected, and enrofloxacin (5 mg/kg, PO, SID for one week) was prescribed. After one week, the subject continued presenting the same clinical manifestations. Another blood test was performed, which also revealed normocytic normochromic anemia, leukocytosis with left shift (67,000/mL; neutrophils: 58,960/ mL, band neutrophils: 2680/mL), eosinophilia (2680/mL) and thrombocytosis (662 £ 10 3 /mL). In view of these results, bone marrow analysis was performed, which revealed an increased myeloid: erythroid ratio (10:1), a moderate increase in mature granulocytes and megakaryocytes and a mild decrease of erythrocytic cells, with all cell lines showing normal morphology. The diagnosis was granulocytic and megakaryocytic hyperplasia. Based on these results and after excluding possible inflammatory/infection reactions, a diagnosis of chronic myeloid leukemia (chronic neutrophilic leukemia) was made.
Hydroxyurea was prescribed at a dosage of 18 mg/kg PO twice daily along with prednisone at a dosage of 1 mg/kg PO once daily. After 35 days on this therapy, the animal was returned to the Veterinary Teaching Hospital because of prostration and lameness. On physical exam, the dog presented exposure of the distal phalanx and nail loss on the left thoracic and pelvic limbs (Fig. 1 ). On complete blood count, a worsened level of anemia was detected (erythrocytes 3.0 £ 106; RR: 5.5 to 8.5 £ 106; hematocrit 26%; RR: 37 to 55%; hemoglobin 7.8 g/dL; RR: 12 to 18 g/dL), with anemia being macrocytic (mean corpuscular volume: 86.7 fl; RR: 60À77 fl) and hypochromic (30%; RR: 31À36), and leukocytosis (56,700/mL; RR: 6.0À18.0 £ 10 3 / mL; neutrophil: 53,865/mL; RR: 3.6À13.8 £ 10 3 /mL) and thrombocytosis (701 £ 10 3 /mL; RR: 180 to 400 £ 10 3 /mL) were observed ( Table 1) .
Regarding dermatological side effects in chemotherapy, onycholysis and pain are classified as grade IV according to the Veterinary Cooperative Oncology Group. 15 Despite the exposure of the distal phalanx in the claws, the animal presented grade IV cutaneous toxicity, associated with complete loss of claws and pain. Pain was assessed based on clinical examination and clinical history. Lameness was evident, and vocalization was evoked when the foot was palpated, with no history of trauma. Pain was likely elicited because of the exposure of the distal phalanx in the claws. Based on the dermatological toxicity, chemotherapy was replaced with chlorambucil at a dosage of 6 mg/m 2 PO once daily. However, after 10 days, the animal presented with prostration and anorexia and a significantly high number of mature neutrophils on complete blood count (white blood cell count of 113,800/mL; neutrophils: 99,006/mL, band neutrophils: 7966/mL; thrombocytosis 731 £ 10 3 /mL) ( Table 1) . Because of these findings, chlorambucil was replaced with cyclophosphamide at a dosage of 300 mg/m 2 once every 21 days for one year. After one week of cyclophosphamide treatment, the patient was lethargic and hyporexic, but severe decreases in the total number of leukocytes (5400/mL) and neutrophils (5076/mL) were observed ( Table 1) . Because of its clinical state, the dog was hospitalized for one day for maintenance fluid therapy using Lactate Ringer plus B complex. After three days, the owner related that the animal was active, with normal appetite and stepping on left limbs better than before. Onycholysis remained until 28 days after suspension of hydroxyurea and involved six claws in total (pelvic and thoracic left limbs). After three months of hydroxyurea suspension, the dog had no lameness and presented complete nail recovery (Fig. 2) . Normal hematologic parameters have been found since the cessation of cyclophosphamide treatment, which lasted for one year. After the cessation of cyclophosphamide treatment, no chemotherapy was performed for six months, and currently, the patient is in complete remission at 575 days after diagnosis.
Chronic myelogenous leukemia is best managed with chemotherapy to control cell proliferation. Hydroxyurea is typically administered for this condition at a dosage of 20 to 25 mg/kg twice daily. In the present case, the dog was prescribed hydroxyurea at 18 mg/kg twice daily, as each capsule contained 500 mg. As the dog weighed 28 kg, it would have needed a dose of 540 mg (at 20 mg/kg, as initially suggested by other authors 16 ). However, as it is possible to reduce the dose by 50% after normalizing the neutrophil blood count, we prescribed a dosage of 18 mg/kg twice daily (36 mg/kg once daily) to avoid the need for capsule manipulation. Hydroxyurea is well tolerated in dogs, even at dosage of 50 mg/ kg SID for 28 days. This was demonstrated by Morton et al., 17 who observed decreases in the values of red blood cells, hemoglobin, hematocrit, white blood cells, neutrophils, monocytes, basophils and platelets 28 days after initiation of treatment with hydroxyurea relative to the values at diagnosis. Some of these abnormalities were observed in this study, such as decreases in red blood cells, hemoglobin, hematocrit and platelets, after 35 days of hydroxyurea treatment. However, this medication was not effective in decreasing the count of white blood cells, which increased after treatment (29,500/ mL vs. 56,700/mL). In addition, the presence of macrocytosis similar megaloblastic-like changes in anemia as appropriate commonly observed in hematological disorders due to myelodysplastic disorders as leukemia 18, 19 was observed, which was reversed after treatment with cyclophosphamide. One study evaluated 467 human patients with myeloid chronic leukemia and found that 270 (57%) of the patients presented anemia, of which 119 (44%) presented macrocytosis. 20 The mechanism of action of hydroxyurea in the bone marrow is well known, but its etiopathogeny regarding dermatological toxicity is poorly understood. One possible mechanism might involve its antiproliferative and cytostatic action in the epithelium. 13, 21 One study evaluated the ultrastructure of cutaneous abnormalities induced after prolonged use of hydroxyurea in three patients who developed severe generalized cutaneous atrophy and revealed abnormalities in the basal lamina and microfibrils in the papillary dermis. 22 Although dermatological toxicity induced by hydroxyurea has been described in human patients and dogs after prolonged use, 1, 17, 21 this case report describes the development of onycholysis after five weeks of use. One limitation of this case report is the unavailability of a histopathology exam. A histopathology of claw biopsies would have provided evidence of whether the claw lesions were secondary to hydroxyurea toxicity. Such an exam would have been important not only for obtaining a more accurate diagnosis of the claw lesions but also for ruling out other possible causes of onychodystrophy, such as lupoid onychodystrophy. The association between the claw lesions and chemotherapy detected here is based solely on the clinical observation that the lesions appeared temporally with the initiation of hydroxyurea and resolved after its discontinuation.
One study in African children with sickle-anemia treated with hydroxyurea noted the development of ungual alterations in three children after 6À8 weeks of use, which were mainly manifested as ungual hyperpigmentation, longitudinal bands in nails and macular hyperpigmentation. 21 The authors of that study suggested that the cutaneous side effects of hydroxyurea may be influenced by ethnicity and pigmentation. Accordingly, it is possible that cutaneous side effects of hydroxyurea may be related to breed predisposition or pigmentation in dogs. Few studies describing onycholysis induced by chemotherapy exist in the veterinary literature. The fact that the patient in this study had pigmented skin associated with the development of cutaneous side effects at a therapeutic dose suggest the possible influence of pigmentation. Further studies are required to investigate the potential role of pigmentation in the development of onycholysis after hydroxyurea treatment in veterinary patients.
Conclusions
To the authors' knowledge, this is the first report of hydroxyureainduced onycholysis within a short-term period in a dog. Clinicians should be aware of this potential unusual adverse effect when using hydroxyurea.
